New app for asthma sufferers goes on market
MELBOURNE: Asthma sufferers know the signs – a tightening in the chest, shortness of breath, rapid heart rate, coughing and wheezing.
They also know the terror of a flare-up; the feeling of choking, suffocating or ‘‘drowning’’, and the fear that this time the monster at their throat might win.
Some of the most vulnerable are small children, whose parents live with the strain of night-time vigils and desperate trips to the emergency department.
About one in nine Australians – 2.7 million people – suffer from asthma, according to the Australian Institute of Health and Welfare. At least 421 people died from the disease in 2015 and the mortality rate is stubbornly hard to shift.
Medical technology innovator Respiri aims to change this with a new connected device, dubbed Wheezo, which records breath sounds to detect and measure ‘‘wheeze rate’’ – the extent of the coarse whistling sound produced when the airways are narrowed and inflamed.
Respiri’s chief executive, Mario Gattino, says: ‘‘Wheezo provides objective, real-time measurement of wheeze and an electronic diary powered by machine learning.
‘‘We’re building a personalised coach and early warning system.’’
Worldwide, the disease affects about 340 million people and kills 1000 a day, according to the 2018 report of the Global Asthma Network.
‘‘That makes it as big as diabetes or cardiovascular disease,’’ Gattino says.
‘‘About 30 per cent are under 15, so we are targeting 100 million people worldwide.
‘‘Our mission is to get them using medications properly when they are young, keep them out of hospital, and really improve quality of life for families.’’
The current best treatment is to give quick-relief medication before an attack becomes serious, but this only works if the warning signs are recognised in time.
Older patients can use peak flow monitors, but the NationalAsthma Council advises parents of younger children to take video or audio recordings and keep a paper diary to identify possible triggers. It’s an arduous and uncertain way to manage a potentially life-threatening condition.
Gattino says: ‘‘Wheezo is the digital solution to the council’s recommendations for standard care. It’s like having your doctor and their stethoscope with you 24/7.’’
Wheezo uses Respiri’sAcoustic Respiratory Monitoring technology to capture breath sounds at the trachea (windpipe).
It then connects to the Respiri backend on the cloud via smart app to request the current local weather conditions and pollen and pollution counts.
This can be combined with other health readings and fed into the machine learning model, where the algorithm looks for patterns and alerts the patient if there is heightened risk. All secure data can be shared via email with the patient’s GP.
Professor Bruce Thompson, Dean of the School of Health Sciences at Swinburne University and President-elect of the Thoracic Society of Australia and New Zealand, is a non-executive director of Respiri.
‘‘Only one in 10 people are fully controlled and there are far too many avoidable hospitalisations and deaths,’’ he says.
‘‘We are conducting short-term studies to determine the clinical relevance of the technology and wheeze rate measurement, and its value to healthcare professionals and their patients.
‘‘We are also in the planning phase oflonger term studies, here in Australia and in the UK, that will determine the impact of the technology on the wider health service.’’
Respiri developed Wheezo from Israeli research in partnership with technology commercialisation company Grey Innovation and creative engineers Two Bulls. The initial batch of units is being built by contract manufacturer SRX Global in
Dandenong. Once volumes scale up, manufacturing will move to SRX Global’s lowcost facility in Malaysia.
Gattino says: ‘‘Our business model is to have a very small in-house team and work with best-inclass third party-providers.’’
Respiri aims to launch Wheezo during 2019, with the support of LIDA Australia, the Customer Engagement arm of M&C Saatchi.
Former Australian cricket captain Michael Clarke has joined Respiri as a Wheezo brand ambassador. Clarke’s three-year-old daughter was rushed to hospital with an attack in November 2018.
Gattino says Respiri holds multi-faceted intellectual property rights over its technology, including copyright in software, engineering patents and trademarks on branding.
The company is about to apply for the European Union CE Mark for Wheezo, quickly followed by Therapeutic Goods Administration and Singapore’s Health Sciences Administration and then US Federal Drug Administration.
‘‘We will test our go-to-market strategy in the UK, Australia and Singapore,’’ Gattino says.
‘‘Then, based on what we know works, we will launch into the rest of Europe and the US in 2020.
Respiri is targeting a significant worldwide market.
AsthmaAustralia says the disease cost the Australian economy about $28 billion in 2015, due to factors including disability and premature death ($24.7 billion), healthcare costs, lost productivity and income support for carers.
The GlobalAsthma Network says the total cost of asthma in 2011in the US alone amounted to $US56 billion ($A78 billion).






